Search Results - "Zerek, Bartłomiej"

Improved cytotoxicity of novel TRAIL variants produced as recombinant fusion proteins by Figiel, Małgorzata, Bonarek, Piotr, Górecki, Andrzej, Pawlak, Sebastian D, Żerek, Bartłomiej, Chęcińska, Beata, Pieczykolan, Jerzy, Dziedzicka-Wasylewska, Marta

“…Abstract The TNF-Related Apoptosis Inducing Ligand (TRAIL) cytokine triggers apoptosis specifically in cancer cells. Susceptibility of a given cell to TRAIL…”
Get full text

Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma by Piechna, Karolina, Żołyniak, Aleksandra, Jabłońska, Ewa, Noyszewska-Kania, Monika, Szydłowski, Maciej, Żerek, Bartłomiej, Kulecka, Maria, Rumieńczyk, Izabela, Mikula, Michał, Juszczyński, Przemysław

“…BackgroundTRAIL (TNF-related apoptosis inducing ligand) exhibits selective proapoptotic activity in multiple tumor types, while sparing normal cells. This…”
Get full text

AD-O53.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L by Pieczykolan, Jerzy S., Kubiński, Konrad, Masłyk, Maciej, Pawlak, Sebastian D., Pieczykolan, Anna, Rózga, Piotr K., Szymanik, Michał, Gałązka, Marlena, Teska-Kamińska, Małgorzata, Żerek, Bartłomiej, Bukato, Katarzyna, Poleszak, Katarzyna, Jaworski, Albert, Strożek, Wojciech, Świder, Robert, Zieliński, Rafał

“…Summary Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors became promising molecules for selective targeting of tumor cells…”
Get full text

Abstract 2276: Induction of apoptosis and inhibition of angiogenesis by novel fusion protein - AD-O54.9 as a new preclinical strategy in cancer treatment by Rózga, Piotr, Pieczykolan, Jerzy, Zerek, Bartłomiej, Pieczykolan, Anna, Gałązka, Marlena, Bukato, Katarzyna, Szymanik, Michał, Jaworski, Albert, Pawlak, Sebastian, Teska-Kamińska, Małgorzata, Grochot-Przęczek, Anna

“…Background For almost two decades tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) has been under extensive development as a potential…”
Get full text

AD-053.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L by PIECZYKOLAN, Jerzy S, KUBINSKI, Konrad, BUKATO, Katarzyna, POLESZAK, Katarzyna, JAWORSKI, Albert, STROZEK, Wojciech, SWIDER, Robert, ZIELINSKI, Rafał, MASLYK, Maciej, PAWLAK, Sebastian D, PIECZYKOLAN, Anna, ROZGA, Piotr K, SZYMANIK, Michał, GALAZKA, Marlena, TESKA-KAMINSKA, Małgorzata, ZEREK, Bartłomiej

Get full text

Novel engineered TRAIL‐based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance by Rozga, Piotr, Kloska, Damian, Pawlak, Sebastian, Teska‐Kaminska, Malgorzata, Galazka, Marlena, Bukato, Katarzyna, Pieczykolan, Anna, Jaworski, Albert, Molga‐Kaczmarska, Anna, Kopacz, Aleksandra, Badyra, Bogna, Kachamakova‐Trojanowska, Neli, Zolnierkiewicz, Olga, Targosz‐Korecka, Marta, Poleszak, Katarzyna, Szymanik, Michal, Zerek, Bartlomiej, Pieczykolan, Jerzy, Jozkowicz, Alicja, Grochot‐Przeczek, Anna

“…Targeting of the TRAIL‐DR4/5 pathway was proposed as a promising approach for specific induction of apoptosis in cancer cells. Clinical trials, however, showed…”
Get full text

An efficient synthesis of indolo[2,3-b]quinoline guanidine derivatives with their in vitro and in vivo study by Sidoryk, Katarzyna, Świtalska, Marta, Rózga, Piotr, Wietrzyk, Joanna, Bujak, Iwona, Żerek, Bartłomiej, Kaczmarek, Łukasz, Cybulski, Marcin

“…An optimization of the guanidylation process by verifying the efficacy of common guanylation reagents in order to obtain the guanidine derivatives of…”
Get full text

Abstract 4471: AD-O64.4 - a novel bioconjugate for tumor-targeted drug delivery by Strozek, Wojciech, Pieczykolan, Anna, Zerek, Bartlomiej, Szymanik, Michal, Jaworski, Albert, Galazka, Marlena, Bukato, Katarzyna, Rozga, Piotr, Pawlak, Sebastian, Poleszak, Katarzyna, Teska-Kaminska, Malgorzata, Pieczykolan, Jerzy

“…Although standard chemotherapy is still one of the most effective treatment for many types of cancer - often causes side effects. Chemotherapeutic agents…”
Get full text

Abstract 2600: Preclinical evaluation of the novel fusion molecule with high dual antiangiogenic and anticancer potential by Pieczykolan, Jerzy S., Pieczykolan, Anna, Rozga, Piotr, Pawlak, Sebastian, Zerek, Bartlomiej, Teska - Kaminska, Malgorzata, Michal, Szymanik, Jaworski, Albert, Erlemann, Karl R., Capala, Jacek

“…Angiogenesis, the process of new blood vessels formation, is essential for tumor growth and metastasis. Since tumors are unable to grow beyond a millimeter…”
Get full text

Abstract 3796: Biochemical and biophysical characterization of AD-O51.4 a novel anticancer biological therapeutic agent with dual mechanism of action by Pawlak, Sebastian D., Pieczykolan, Jerzy S., Zerek, Bartlomiej, Poleszak, Katarzyna, Teska-Kaminska, Malgorzata, Galaska, Marlena, Szymanik, Michal, Jaworski, Albert, Pieczykolan, Anna, Bukato, Katarzyna, Strozek, Wojciech, Rozga, Piotr K.

“…Background Cancer growth and development is tightly related to both new vessels formation for tissue remodeling and inhibition of anti-apoptotic signals…”
Get full text

Abstract 2773: AD-O56.9: A fusion of TRAIL/Apo2L with a membrane disrupting peptide as a novel anticancer therapeutic by Zerek, Bartlomiej Maciej, Szymanik, Michal, Rozga, Piotr Kamil, Pieczykolan, Anna, Galazka, Marlena, Bukato, Katarzyna, Jaworski, Albert, Poleszak, Katarzyna, Pawlak, Sebastian Dominik, Teska-Kaminska, Malgorzata, Strozek, Wojciech, Pieczykolan, Jerzy Szczepan

“…Background The tumor necrosis factor related apoptosis-inducing ligand (TRAIL/Apo2L) is a member of the TNF superfamily that initiates apoptosis of tumor cells…”
Get full text

Abstract 5073: Novel fusion molecule with high dual antiangiogenic and anticancer potential by Pieczykolan, Jerzy S., Rozga, Piotr, Pieczykolan, Anna, Zerek, Bartlomiej, Pawlak, Sebastian D., Szymanik, Michal, Jaworski, Albert, Galazka, Marlena, Wiciejowska, Katarzyna, Strozek, Wojciech, Teska - Kaminska, Malgorzata, Kutner, Lukasz, Grochot - Przeczek, Anna, Kahmakowa - Trojanowska, Neli

“…One of the most important mechanisms of tumorgenesis is formation of new blood vessels and tissue remodeling. Vascular endothelial growth factor (VEGF) is one…”
Get full text

Abstract 5488: Fusion protein capable to initiate two apoptotic pathways in cancer cells resistant to classical PARA's by Pieczykolan, Jerzy S., Pawlak, Sebastian D., Zerek, Bartlomiej M., Rozga, Piotr K., Pieczykolan, Anna, Szymanik, Michal, Jaworski, Albert, Galazka, Marlena, Strozek, Wojciech, Wiciejowska, Katarzyna, Teska-Kaminska, Malgorzata, Kutner, Lukasz

“…Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) is a promising antitumor agent, but its clinical utility in human malignancies is limited…”
Get full text